Lyell Immunopharma Shares Are Trading Higher After the Company Announced That Three Abstracts Highlighting Its Pipeline of Clinical Product Candidates and Anti-exhaustion Technology Have Been Accepted for Presentation at the 39th Annual Meeting of the...

Benzinga · Oct 4 21:12

Lyell Immunopharma Shares Are Trading Higher After the Company Announced That Three Abstracts Highlighting Its Pipeline of Clinical Product Candidates and Anti-exhaustion Technology Have Been Accepted for Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Lyell Immunopharma Shares Are Trading Higher After the Company Announced That Three Abstracts Highlighting Its Pipeline of Clinical Product Candidates and Anti-exhaustion Technology Have Been Accepted for Presentation at the 39th Annual Meeting of the...

Lyell Immunopharma Shares Are Trading Higher After the Company Announced That Three Abstracts Highlighting Its Pipeline of Clinical Product Candidates and Anti-exhaustion Technology Have Been Accepted for Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer.

Risk Disclaimer